Mass. biotechs Kiniksa, Scholar Rock snag combined $228M in IPOs

Two more Massachusetts drug developers have hit the Nasdaq, raising a combined $228 million in another sign that the biotech industry ’s IPO window remains wide open. Lexington-based Kiniksa Pharmaceuticals, which is developing drugs for autoimmune and inflammatory diseases, said Wednesday that it raised $163 million by offering its shares under the ticker “KNSA.” Scholar Rock, a Cambridge startup focused on muscle-wasting disorders, also scored $75 million in its market debut, with shares…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news